Items Tagged ‘dexamethasone’

November 29th, 2016

Darzalex® Approved for Additional Indications in Multiple Myeloma

By

The United States Food and Drug Administration (FDA) has approved Darzalex® (daratumumab) for the treatment of multiple myeloma among patients who have received at least one prior therapy. The new FDA indication also requires that daratumumab be used in combination with lenalidomide and dexamethasone, or in combination with bortezomib and dexamethasone. Daratumumab is already approved […]

View full entry

Tags: blood cancer, bortezomib, CASTOR, CD38, Darzalex, dexamethasone, fda, lenalidomide, Multiple Myeloma, News, POLLUX, Recurrent Multiple Myeloma


October 12th, 2016

HOVON Trial: Autologous Stem Cell Transplant Remains Superior to Novel Agents for Treatment of Multiple Myeloma

By

A large, comparative, phase III HOVON clinical trial recently confirmed that upfront autologous stem cell transplantation (ASCT) should still be the treatment of choice in younger patients with newly diagnosed multiple myeloma (MM). The findings of this trial clearly demonstrated that ASCT should remain the preferred treatment for younger patients with MM. The clinical trial […]

View full entry

Tags: ASCT, bortezomib, clinical trial, cyclophosphamide, dexamethasone, HOVON, Multiple Myeloma, News, Stem Cell Transplant, velcade


May 16th, 2016

Hydrocortisone Significantly Improves Neuropsychological Issues in Some Children with Leukemia

By

The use of physiologic doses of hydrocortisone appears to significantly improve neuropsychological issues caused by treatment including dexamethasone among children with acute lymphoblastic leukemia. These results were published as an early release article in the Journal of Clinical Oncology. Acute lymphoblastic leukemia (ALL) is a fast-growing form of leukemia, and is a common type of […]

View full entry

Tags: Acute Lymphoblastic Leukemia, all, children, cortisol, dexamethasone, hydrocortisone, Leukemia, News


January 26th, 2016

Combo Therapy of Kyprolis plus Dexamethasone Approved for Recurrent Multiple Myeloma

By

The United States Food and Drug Administration (FDA) recently approved a new treatment combination consisting of Kyprolis (carfilzomib) plus dexamethasone for patients with relapsed or refractory multiple myeloma. Multiple myeloma is a type of blood cancer that affects certain immune cells called plasma cells. Healthy plasma cells produce proteins called antibodies that are an important […]

View full entry

Tags: carfilzomib, dexamethasone, ENDEAVOR, fda, kyprolis, Multiple Myeloma, News, Recurrent Multiple Myeloma


December 7th, 2015

FDA Approves Empliciti for Multiple Myeloma

By

The United States Food and Drug Administration (FDA) has approved Empliciti (elotuzumab) for the treatment of patients with multiple myeloma who have received prior therapies. The indication specifies that Empliciti is to be used in combination with lenalidomide and dexamethasone for the treatment of patients who have received one to three prior therapies for multiple […]

View full entry

Tags: dexamethasone, elotuzumab, Empliciti, fda, lenalidomide, Multiple Myeloma, News, Recurrent Multiple Myeloma, SLAMF7